Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study

Table 5 Clinicopathologic variables associated with progression-free survival

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	*P-value*	Adjusted HR	95% CI	*P-value*
Histology
Non-endometrioid vs. endometrioid	3.610	1.463–8.909	0.005	7.322	2.477–21.646	< 0.001
FIGO stage
IVB vs. IIIC	5.308	0.713–39.521	0.103	–	–	–
CA-125 at diagnosis, IU/ml
≥190 vs. <190	1.608	0.702–3.682	0.261	–	–	–
Residual tumor after IDS
Any RT vs. NGR	2.427	1.008–5.844	0.048	5.934	2.035–17.302	0.001

Abbreviations: FIGO International Federation of Gynecology and Obstetrics, IDS Interval debulking surgery, RT residual tumor, NGR no gross residual, HR hazard ratio, 95% CI 95% confidence interval

ISSN: 1471-2407